BlackRock
DSGN icon

BlackRock’s Design Therapeutics DSGN Stock Holding History

BlackRock’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38.5M Buy
2,660,024
+526,260
+25% +$6.56M ﹤0.01% 2838
2026
Q1 		$22.7M Buy
2,133,764
+16,608
+0.8% +$168K ﹤0.01% 3005
2025
Q4 		$19.9M Buy
2,117,156
+72,768
+4% +$570K ﹤0.01% 3115
2025
Q3 		$15.4M Sell
2,044,388
-351,355
-15% -$1.76M ﹤0.01% 3243
2025
Q2 		$8.07M Sell
2,395,743
-84,220
-3% -$315K ﹤0.01% 3528
2025
Q1 		$9.57M Sell
2,479,963
-99,636
-4% -$475K ﹤0.01% 3338
2024
Q4 		$15.9M Buy
2,579,599
+220,802
+9% +$1.28M ﹤0.01% 3185
2024
Q3 		$12.7M Buy
2,358,797
+53,849
+2% +$253K ﹤0.01% 3283
2024
Q2 		$7.72M Buy
2,304,948
+30,757
+1% +$120K ﹤0.01% 3516
2024
Q1 		$9.16M Sell
2,274,191
-106,051
-4% -$283K ﹤0.01% 3390
2023
Q4 		$6.31M Sell
2,380,242
-23,673
-1% -$54.2K ﹤0.01% 3599
2023
Q3 		$5.67M Sell
2,403,915
-590,136
-20% -$2.75M ﹤0.01% 3607
2023
Q2 		$18.9M Sell
2,994,051
-191,840
-6% -$1.17M ﹤0.01% 3076
2023
Q1 		$18.4M Sell
3,185,891
-322,133
-9% -$2.41M ﹤0.01% 3020
2022
Q4 		$36M Sell
3,508,024
-91,101
-3% -$1.23M ﹤0.01% 2691
2022
Q3 		$60.2M Buy
3,599,125
+59,189
+2% +$1.18M ﹤0.01% 2303
2022
Q2 		$49.6M Buy
3,539,936
+389,116
+12% +$5.26M ﹤0.01% 2504
2022
Q1 		$50.9M Buy
3,150,820
+935,196
+42% +$14.3M ﹤0.01% 2580
2021
Q4 		$47.4M Buy
2,215,624
+902,960
+69% +$15.5M ﹤0.01% 2694
2021
Q3 		$19.3M Sell
1,312,664
-90,678
-6% -$1.51M ﹤0.01% 3303
2021
Q2 		$27.9M Buy
1,403,342
+612,323
+77% +$15.5M ﹤0.01% 3098
2021
Q1 		$23.7M Buy
+791,019
New +$26.7M ﹤0.01% 3091

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return

BlackRock's DSGN Position: Q2 2026 in Review

BlackRock increased its Design Therapeutics (DSGN) stake by 25% in Q2 2026, buying an estimated $6.56M and bringing the position to 2,660,024 shares worth $38.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2838.

BlackRock first reported a position in DSGN in Q1 2021 and has held it in 22 quarters since. The position peaked at $60.2M in Q3 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • BlackRock held 2,660,024 shares of Design Therapeutics worth $38.5M as of Q2 2026.
  • BlackRock bought 526,260 Design Therapeutics shares in Q2 2026, an estimated $6.56M.
  • Design Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2838 holding.
  • BlackRock first reported a position in Design Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • BlackRock's Design Therapeutics position peaked at $60.2M in Q3 2022.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.